Phase I study on patients with oxi refractory/intolerant KRAS mutant CRC
coloCan
Member Posts: 1,944 Member
announced this date by Calgary, Canada-based Oncolytics Biotech, which will consist of FOLFIRI (Leucovorin,5FU and Irinotecan)with this new thing called Reolysin (REO). For more info see www.prnewsire.com or
rttnews.com
Hope this helps someone
rttnews.com
Hope this helps someone
0
Discussion Boards
- 120.1K All Discussion Boards
- 6 CSN Information
- 6 Welcome to CSN
- 120.3K Cancer specific
- 2.8K Anal Cancer
- 437 Bladder Cancer
- 302 Bone Cancers
- 1.6K Brain Cancer
- 28.3K Breast Cancer
- 384 Childhood Cancers
- 27.8K Colorectal Cancer
- 4.6K Esophageal Cancer
- 1.1K Gynecological Cancers (other than ovarian and uterine)
- 12.7K Head and Neck Cancer
- 6.3K Kidney Cancer
- 654 Leukemia
- 772 Liver Cancer
- 4.1K Lung Cancer
- 5K Lymphoma (Hodgkin and Non-Hodgkin)
- 228 Multiple Myeloma
- 7.1K Ovarian Cancer
- 39 Pancreatic Cancer
- 481 Peritoneal Cancer
- 5.1K Prostate Cancer
- 1.2K Rare and Other Cancers
- 528 Sarcoma
- 699 Skin Cancer
- 640 Stomach Cancer
- 190 Testicular Cancer
- 1.5K Thyroid Cancer
- 5.7K Uterine Cancer
- 6.2K Other Discussion Boards